A London-based clinic has become the first commercial facility in Europe dedicated to running clinical trials with psychedelic compounds. Clerkenwell Health, based in central London, opened in 2022 C.E. with an initial focus on psilocybin — the psychedelic compound found in certain mushrooms — targeting patients in palliative care and those living with terminal diagnoses.
At a glance
- Psilocybin clinical trials: Clerkenwell Health launched trials in central London beginning in August 2022 C.E., making it the first commercial European site focused on psychedelic-assisted therapy research.
- Palliative care focus: Initial trials target patients facing end-of-life and terminal diagnoses, a population where conventional mental health treatments often fall short.
- Psychedelic research ecosystem: The clinic aims to position the U.K. as a global hub for commercial psychedelic research, working with mental health experts and drug developers internationally.
Why this clinic matters
Psilocybin has been the subject of growing academic interest for years, with university-led studies at institutions such as Imperial College London and Johns Hopkins University in the U.S. showing promising results for treatment-resistant depression and end-of-life anxiety. But academic trials and commercial research infrastructure are different animals.
Commercial facilities like Clerkenwell Health bridge that gap. They provide the specialized environments, regulatory compliance, and scalable capacity that pharmaceutical companies need to push promising compounds through late-stage clinical trials — the final hurdle before any treatment can be considered for regulatory approval.
“Psychedelic-assisted therapy could be groundbreaking for mental health treatment, and the U.K. is well placed to be at the vanguard of that as a global leader in clinical trials,” said Tom McDonald, CEO of Clerkenwell Health. “Our aim is to establish the U.K. as the heart of the commercial psychedelic research ecosystem, working closely with mental health experts and drug developers around the world to tackle some of the most complex mental health conditions.”
A specialized and growing field
Running psychedelic-assisted therapy trials is technically demanding. The sessions require trained therapists present throughout, carefully controlled settings, and strict patient screening. That specialization has created a bottleneck.
Peter Rands, CEO of Small Pharma — a company trialing dimethyltryptamine (DMT) as a treatment for depression — described the challenge. “A set of very specific conditions need to be met to do psychedelic-assisted therapy; it’s quite a specialized area of expertise,” he said. “The eight or so companies in clinical trials with psychedelic-based medicines heavily rely on contract research organizations to do this kind of research — particularly as they begin to enter late-stage clinical trials.”
Clerkenwell Health positions itself as exactly that kind of contract research organization, serving multiple drug developers at once rather than running trials for a single compound or company. That model could dramatically accelerate how quickly different psychedelic compounds — psilocybin, DMT, MDMA, ketamine, and others — move through the research pipeline.
The broader mental health case
The conditions researchers hope psychedelics might help treat are among the hardest to address. Mood and anxiety disorders, addiction, post-traumatic stress disorder, and end-of-life psychological distress all carry heavy burdens for patients and health systems. Existing medications work well for some, but a substantial share of patients don’t respond adequately to current treatments.
That treatment gap is part of what makes psychedelic research so compelling. Studies published in The Lancet Psychiatry have found that psilocybin therapy produced rapid reductions in depression scores in patients who hadn’t responded to standard antidepressants. Research in the New England Journal of Medicine compared psilocybin against a leading antidepressant and found comparable effects on depression at six weeks. For patients facing a terminal diagnosis — Clerkenwell Health’s starting focus — earlier trials at NYU and Johns Hopkins showed significant and lasting reductions in anxiety and depression after just one or two psilocybin sessions.
None of this means psilocybin is a proven, ready-to-prescribe treatment. Regulatory approval remains years away in most countries, and the legal status of psilocybin as a controlled substance means every clinical use must go through rigorous licensing. Questions about optimal dosing, long-term effects, potential for harm in vulnerable populations, and how to train therapists at scale are all still open. Building out commercial trial infrastructure is a necessary step toward answering them — but it is only one step.
What comes next
The opening of a dedicated commercial facility signals that the field has moved beyond proof-of-concept. A 2021 C.E. review in Nature Medicine noted that psychedelic-assisted therapies were advancing into larger, more rigorous trials — but that the lack of specialized research sites was a constraint on the pace of that work.
Clerkenwell Health’s model, if successful, could inspire similar facilities in other European countries. The U.K.’s post-Brexit regulatory environment gives it some flexibility in clinical trial design, which McDonald cited as an advantage. Whether that translates into a durable lead in psychedelic research depends on whether the science continues to hold up as trials scale — and whether regulators in the U.K. and elsewhere are willing to move at the pace the science may eventually support.
For now, the clinic’s opening represents a meaningful shift: psychedelic medicine moving from academic curiosity to structured, commercially funded clinical science, with real patients, real oversight, and real stakes.
Read more
For more on this story, see: The Optimist Daily — First European psychedelic drug trial clinic opens in the U.K.
For more from Good News for Humankind, see:
- Renewables now make up at least 49% of global power capacity
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- The Good News for Humankind archive on medical research
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
